NASDAQ:IPHA - Innate Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.25
  • Forecasted Upside: 95.04 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.23
▼ -0.17 (-3.86%)
1 month | 3 months | 12 months
Get New Innate Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPHA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.25
▲ +95.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Innate Pharma in the last 3 months. The average price target is $8.25, with a high forecast of $13.00 and a low forecast of $4.75. The average price target represents a 95.04% upside from the last price of $4.23.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in Innate Pharma. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2021SVB LeerinkBoost Price TargetMarket Perform$5.00 ➝ $7.00Medium
i
Rating by D. Graybosch at SVB Leerink LLC
3/19/2021SVB LeerinkBoost Price TargetMarket Perform$5.00 ➝ $7.00Medium
i
Rating by D. Graybosch at SVB Leerink LLC
2/4/2021HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by S. Ramakanth at HC Wainwright
12/15/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$7.00 ➝ $5.00Low
i
Rating by D. Graybosch at SVB Leerink LLC
12/14/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $11.50Low
i
Rating by S. Ramakanth at HC Wainwright
11/23/2020The Goldman Sachs GroupInitiated CoverageNeutral$4.75High
i
10/9/2020HC WainwrightReiterated RatingBuy$13.00High
i
9/9/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralLow
i
9/9/2020SVB LeerinkLower Price TargetOutperform$9.00 ➝ $7.00High
i
5/14/2020SVB LeerinkLower Price TargetOutperform$10.00 ➝ $9.00Low
i
Rating by D. Graybosch at SVB Leerink LLC
11/26/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by S. Ramakanth at HC Wainwright
11/11/2019SVB LeerinkReiterated RatingOutperformMedium
i
Rating by D. Graybosch at SVB Leerink LLC
(Data available from 4/19/2016 forward)
Innate Pharma logo
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Read More

Today's Range

Now: $4.23
$4.23
$4.30

50 Day Range

MA: $4.42
$4.20
$4.74

52 Week Range

Now: $4.23
$3.55
$8.23

Volume

129 shs

Average Volume

37,641 shs

Market Capitalization

$334.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Innate Pharma?

The following Wall Street analysts have issued reports on Innate Pharma in the last twelve months: Bryan, Garnier & Co, HC Wainwright, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for IPHA.

What is the current price target for Innate Pharma?

3 Wall Street analysts have set twelve-month price targets for Innate Pharma in the last year. Their average twelve-month price target is $8.25, suggesting a possible upside of 95.0%. HC Wainwright has the highest price target set, predicting IPHA will reach $13.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.75 for Innate Pharma in the next year.
View the latest price targets for IPHA.

What is the current consensus analyst rating for Innate Pharma?

Innate Pharma currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IPHA, but not buy more shares or sell existing shares.
View the latest ratings for IPHA.

What other companies compete with Innate Pharma?

How do I contact Innate Pharma's investor relations team?

Innate Pharma's physical mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company's listed phone number is 33-4-30-30-30-30 and its investor relations email address is [email protected] The official website for Innate Pharma is www.innate-pharma.com.